surmount-1 trial tirzepatide obesity without diabetes weight loss (ZEPBOUND) Approved for Chronic Management in Adults with ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or Tirzepatide once weekly for the

The physical changes did come, but that wasnt the most profound part of the journey

For several SOCs with the highest number of adverse reactions, the median TTOs were all less than one week such as administration site conditions (4.91 [0.6324.88] days) and gastrointestinal disorders (5.57 [0.7527.09] days)

Some manufacturers report even longer stability windows under optimal conditions

If you are on thyroid hormone medication, prior to starting Tirzepatide , please review the timing of taking your thyroid hormone medication with the doctor who prescribes it as it may need to be adjusted

Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) due to thyroid C-cell tumor findings in rodent studies

Theres a theoretical risk of thyroid C-cell tumours based on animal studies, though this hasnt been confirmed in humans